A growing understanding of rosacea pathophysiology and the emergence of treatments that target specific manifestations of the disorder, including persistent facial erythema, are advancing the quality of care. A clearer sense of diagnostic criteria and the advantages and limitations of the scope of therapies is essential so dermatologists and other clinicians who manage patients with rosacea can devise treatment plans that are tailored to the pattern and severity of individual patients’ symptoms across the rosacea spectrum.
Dermatologists and other healthcare professionals who provide care for patients with rosacea
At the conclusion of this activity, participants should be better able to:
Describe current theories of the pathophysiology of rosacea
Identify the spectrum of clinical signs and symptoms of rosacea, including its characteristic persistent facial erythema
Assess the risks, benefits, safety profile, and limitations of current and emerging treatments for rosacea
Individualize rosacea treatment plans according to specific manifestations, symptom severity, and other patient characteristics
Counsel and educate patients with rosacea to ensure correct and consistent adherence to treatment recommendations
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
ACTIVITY CHAIR James Q. Del Rosso, DO, FAOCD Clinical Professor of Dermatology Touro University College of Osteopathic Medicine Henderson, NV Dermatology Program Residency Director Valley Hospital Medical Center Las Vegas, NV
Dr. Del Rosso discloses the receipt of consulting, speaker’s bureau and/or contracted research fees from the following: Allergan, Aqua/Almirall, Bayer, BiopharmX, Celgene, Cutanea, Dermira, Ferndale, Foamix, Galderma, Genentech, LEO Pharma, Novan, Novartis, Pfizer, Promius, Sebacia, Sun Pharma, Unilever, and Valeant.
FACULTY Diane S. Berson, MD, FAAD Associate Clinical Professor of Dermatology Weill Medical College of Cornell University New York-Presbyterian Hospital New York, NY
Dr. Berson discloses the receipt of consulting, speaker's bureau, and/or contracted research fees for the following: Aclaris Therapeutics Inc., Allergan, Bayer Pharmaceuticals Company, Ferndale Pharma Group; Galderma, Johnson & Johnson, P & G Dermatology, SkinFix, Inc., and Valeant Pharmaceuticals International.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education, the National Rosacea Society, and Allergan. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.